Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study.

BACKGROUND

Anticancer drugs can interact with the tumour microenvironment and their effects could be exploited to favour anticancer immune response. Eribulin contributes to tumour vasculature remodelling and transforming growth factor β (TGF-β) modulation in experimental models and in humans. We performed a prospective, translational, exploratory analysis of the levels of circulating cytokines at different time points in patients with metastatic breast cancer treated with eribulin.

METHODS

TGF-β, tumour necrosis factor α, vascular endothelial growth factor, IL-6, IL-8, IL-10, IL-21 and C-C motif chemokine ligand-2 levels were assessed in peripheral blood samples obtained from seven healthy volunteers and 41 patients at baseline (T

RESULTS

In the 41 patients, high IL-6 and IL-8 (above the median) at T

CONCLUSIONS

We observed a significant correlation between TGF-β decline during eribulin treatment and outcome in patients with metastatic breast cancer. Altogether, our data suggest that eribulin treatment might interfere with the tumour microenvironment.

Informations de copyright

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

Déclaration de conflit d'intérêts

Competing interests: OG reports grants from Eisai, during the conduct of the study; personal fees from Eisai, personal fees from Pfizer, personal fees from Novartis, personal fees and other from Celgene, personal fees from Amgen, other from Roche, outside the submitted work; AM reports personal fees and other from Eisai, personal fees and other from Novartis, personal fees from Astra Zeneca, personal fees from Teva, personal fees from Pfizer, personal fees and other from Celgene, other from Ipsen, outside the submitted work; FM reports personal fees and other from Roche, personal fees from Novartis, personal fees from Pfizer, personal fees from Eli Lilly, outside the submitted work; AMV reports personal fees from Pierre Fabre, personal fees and other from Celgene, personal fees from Epionpharma, other from Roche, other from Eli Lilly, other from Bristol Myers Squibb, other from Pfizer, outside the submitted work; PV reports personal fees and other from Bristol Myers Squibb, personal fees from Pierre Fabre, other from Janssen, other from Roche, other from Pfizer, other from Novartis, other from Astellas, outside the submitted work; MDM reports personal fees from Merck Sharp & Dohme, personal fees from Bristol Myers Squibb, personal fees from Eisai, personal fees from Janssen, personal fees from Astellas, personal fees from Astra Zeneca, personal fees from Pfizer, personal fees from Takeda, grants from Tesaro, outside the submitted work; MM reports personal fees and other from Astra Zeneca, personal fees and other from Merck Serono, personal fees and other from Bristol Myers Squibb, personal fees from Merck Sharp & Dohme, personal fees and other from Pfizer, outside the submitted work; the remaining authors declare no competing interests.